Last reviewed · How we verify
Intravitreal triamcinolone injections
Triamcinolone is a corticosteroid that suppresses intraocular inflammation by inhibiting inflammatory mediators and immune cell activation in the vitreous.
Triamcinolone is a corticosteroid that suppresses intraocular inflammation by inhibiting inflammatory mediators and immune cell activation in the vitreous. Used for Diabetic macular edema, Retinal vein occlusion with macular edema, Uveitic macular edema.
At a glance
| Generic name | Intravitreal triamcinolone injections |
|---|---|
| Also known as | - KENACORT RETARD, - Triamcinolone Acetonid |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Triamcinolone acetonide is a synthetic glucocorticoid that reduces inflammation through multiple pathways including inhibition of phospholipase A2, decreased production of inflammatory cytokines (IL-1, IL-6, TNF-α), and suppression of immune cell infiltration. When injected intravitreally, it achieves high local concentrations in the posterior segment while minimizing systemic exposure, making it effective for treating intraocular inflammatory conditions.
Approved indications
- Diabetic macular edema
- Retinal vein occlusion with macular edema
- Uveitic macular edema
- Age-related macular degeneration with choroidal neovascularization
Common side effects
- Elevated intraocular pressure
- Cataract progression
- Endophthalmitis
- Vitreous hemorrhage
- Retinal detachment
- Floaters
Key clinical trials
- A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) (PHASE2)
- Comparison of Intravitreal Bevacizumab Injection with Combination of Suprachoroidal Triamcinolone Acetonide Along with Intravitreal Bevacizumab Injection in the Treatment of Diabetic Macular Edema in Pseudophakic Patients (PHASE4)
- IVB for Post-vitrectomy Hemorrhage in Diabetic Eyes (NA)
- Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization (PHASE2, PHASE3)
- Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study (PHASE3)
- Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy (PHASE4)
- Triamcinolone vs. Laser for Diabetic Macular Edema (NA)
- Corticosteroid Injection Combined With Cataract Surgery in Diabetic Eyes. (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: